Welcome to our dedicated page for Solana news (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Solana stock.
Solana Company reports developments as a Nasdaq-listed company with a digital asset treasury dedicated to acquiring and holding Solana tokens (SOL) and a legacy neurotechnology medical-device business. News commonly covers SOL accumulation, staking rewards, NAV-per-share capital strategy, ATM and registered-direct equity financing, share repurchases, and financial results shaped by digital-asset fair value changes.
Company updates also describe institutional Solana infrastructure initiatives in Asia-Pacific, including validator and staking infrastructure, qualified-custody borrowing against natively staked SOL, and ecosystem partnerships with organizations such as Jito Foundation, Anchorage Digital, and Kamino.
Helius Medical Technologies (Nasdaq: HSDT) has announced that Health Canada has expanded the indication for its Portable Neuromodulation Stimulator (PoNS) device. The device is now approved for use as a short-term treatment (14 weeks) for gait deficits due to mild and moderate stroke symptoms, in addition to existing approvals for chronic balance deficits from traumatic brain injury (TBI) and gait deficits from multiple sclerosis (MS). This expansion addresses a significant medical need for approximately 878,000 Canadians living with stroke, providing clinically significant improvements in gait and reducing fall risks. The company continues to explore further applications of PoNS therapy.
Helius Medical Technologies (NASDAQ: HSDT) has announced it will release its fourth quarter and full year 2022 financial results on March 9, 2023, after market close. The company's conference call will be hosted by CEO Dane C. Andreeff and CFO Jeffrey S. Mathiesen at 4:30 PM ET that same day. Helius focuses on innovative neuromodulation therapies for balance and gait deficits, with its main product, the Portable Neuromodulation Stimulator (PoNS), aimed at treating neurologic deficits. PoNS is indicated for use in patients with mild-to-moderate MS symptoms and authorized for sale in Canada and Australia for related conditions.
Helius Medical Technologies (Nasdaq:HSDT) announced that CEO Dane Andreeff and CFO Jeff Mathiesen will present at the 35th Annual ROTH Conference from March 12-14, 2023, in Laguna Niguel, CA. Their presentation is scheduled for March 13, 2023, at 1:30 PM PT. Investors can access the webcast via the provided link. Helius specializes in non-implantable neurotechnologies aimed at addressing neurologic deficits, with a focus on its Portable Neuromodulation Stimulator (PoNS), used for improving balance and gait in patients with multiple sclerosis. The PoNS device is approved for short-term treatment in the US, Canada, and Australia.
Helius Medical Technologies (NASDAQ: HSDT) announced its participation in the American Physical Therapy Association Combined Sections Meeting (CSM) from Feb. 23-25, 2023. The company will showcase its innovative Portable Neuromodulation Stimulator (PoNS®), designed to treat gait and balance deficits in patients with multiple sclerosis (MS). For the first time, Helius will offer free on-site training for physical therapists, enabling them to become registered PoNS instructors. This training session aims to empower therapists to effectively utilize PoNS Therapy in conjunction with exercise, enhancing patient outcomes.
Helius Medical Technologies (HSDT) reported preliminary, unaudited financial results for Q4 and the full year of 2022. Q4 revenue is projected at $275,000 to $285,000, marking a roughly 40% increase from Q3 2022. Full year revenue is anticipated between $780,000 and $790,000, up about 50% from 2021. The year-end cash balance is expected to be $14.5 million, down from $16.7 million at the end of Q3 2022. The company has launched a telehealth e-commerce site and an online module for physical therapists to enhance access and training for PoNS Therapy.
Helius Medical Technologies (Nasdaq:HSDT) announced that CEO Dane Andreeff and CFO Jeff Mathiesen will present at the Virtual Q1 Investor Summit Microcap Event on January 26, 2023, at 9:30 AM ET. Investors interested in one-on-one meetings can register online. Helius focuses on neurological wellness through non-implantable technologies that enhance the brain's compensation ability and promote neuroplasticity. Their primary product, the Portable Neuromodulation Stimulator (PoNS), is designed for treating gait deficits due to multiple sclerosis and is approved for use in the U.S., Canada, and Australia.
Helius Medical Technologies (Nasdaq:HSDT) announced the addition of Neurology Center of New England (NCNE) to its Therapeutic Experience Program (TEP), aiming to assess the adherence to PoNS therapy for gait improvement in Multiple Sclerosis (MS) patients. NCNE will contribute to a multi-center observational trial, enhancing understanding of PoNS therapy's real-world impact on MS treatment. The study will involve 50-60 participants at various Centers of Excellence, with enrollment beginning in Q4 2022 and continuing into 2023.
Helius Medical Technologies (NASDAQ: HSDT) has extended its Patient Therapy Access Program (PTAP) until June 30, 2023, allowing more Americans with multiple sclerosis (MS) to access PoNS Therapy™ at a reduced cost. This initiative, which began in June 2022, subsidizes therapy for those with a prescription and medical necessity letter. The PoNS device stimulates neural pathways to improve gait. Helius aims to enhance accessibility to this innovative neurotechnology, focusing on improving the mobility and quality of life for individuals with MS.
Helius Medical Technologies (NASDAQ: HSDT) has launched a new e-commerce site in partnership with UpScript to improve accessibility for Americans with gait issues. The Portable Neuromodulation Stimulator (PoNS®) device is now available online, allowing patients to receive it directly at home. This telehealth initiative is expected to streamline treatment for multiple sclerosis (MS) patients, enhancing their journey toward better mobility while still requiring physical therapist involvement.
Helius Medical Technologies (HSDT) announced on December 30, 2022, that its independent directors approved an equity award under its 2021 Inducement Plan for a new employee. The award includes an option to purchase 50,000 shares at an exercise price of $0.215 per share, the closing price on the grant date. The option vests over four years and has a ten-year term. Helius specializes in neurotechnology, aiming to enhance neurologic wellness through devices like the Portable Neuromodulation Stimulator (PoNS), which addresses gait deficits in multiple sclerosis.